REVIEW article
Front. Cell. Infect. Microbiol.
Sec. Intestinal Microbiome
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1638372
This article is part of the Research TopicGut microbiome-driven Pathogenesis and Intervention Strategies in Liver DiseasesView all 4 articles
Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective
Provisionally accepted
Xing-Yu Luo1
Wei-Bin Huang2
Chuang-Hui Lu1Zi-Xuan Feng1
Sui Shen1Ming-Zheng Chen1Wu Gu1
Shu-Sen Zheng1
Zhe Yang1*- 1Department of Hepatobiliary and Pancreatic Surgery, Shulan Hospital, Hangzhou, China
- 2Wenzhou Medical University, Wenzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Nonalcoholic fatty liver disease (NAFLD) has a global prevalence of 20%-33%, and has become the main cause of chronic liver disease. Apart from lifestyle modification therapy, there is currently no definitive pharmacological treatment, thus there is an urgent need to find effective intervention strategies to treat NAFLD. With the discovery of the important role of gut microbes in the pathogenesis of NAFLD, research on the prevention and treatment of non-alcoholic fatty liver disease by probiotics is increasing. At present, many studies have confirmed the role of probiotic regulation in the treatment of NAFLD, which can reduce the level of transaminase and liver fibrosis in patients and protect the liver. The clinical application of probiotics includes single species such as Lactobacillus and Bifidobacteria, as well as synbiotics with different compositions. This article reviews the therapeutic effects of probiotics on NAFLD and the mechanisms by which probiotics directly or indirectly affect the disease. Further research is needed to fully understand the specific underlying mechanisms between probiotics, gut microbes, and NAFLD, and more large-scale clinical trials are needed to evaluate probiotics for the treatment of NAFLD.
Keywords: probiotic, nonalcoholic fatty liver disease, application, Mediating mechanism, Future perspective
Received: 30 May 2025; Accepted: 12 Aug 2025.
Copyright: © 2025 Luo, Huang, Lu, Feng, Shen, Chen, Gu, Zheng and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhe Yang, Department of Hepatobiliary and Pancreatic Surgery, Shulan Hospital, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.